Bhanji Kundaria, MD
Hematology-Oncology · Santa Maria, CANPI 1619906872
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,110 of the $10,964 with a category attached, or 83.1%. 14 manufacturers reported payments, led by Johnson & Johnson at 45.0% of the total. Reporting peaked in 2019 at $7,730 and has fallen 99.4% since, to $44 in 2022.
Across 22 payments — averaging $498.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$5K
- AstraZeneca$3K
- GSK$2K
- Bristol Myers Squibb$1K
- Incyte Corporation$63
- Takeda Pharmaceuticals U.S.A., Inc.$22
- plus $131 from 8 others
What the payments were for
- Consulting fees$9,11083%
- Travel & lodging$1,52014%
- Food & beverage$3343%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $4,930 |
| AstraZeneca | 2 | $2,823 |
| GSK | 1 | $1,840 |
| Bristol Myers Squibb | 1 | $1,155 |
| Incyte Corporation | 3 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Pfizer | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Gilead | 1 | $19 |
| Merck | 1 | $17 |
| Servier Pharmaceuticals LLC | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Seagen Inc. | 1 | $13 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,964 in reported general payments places this provider in the 60th percentile of 53 hematology-oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology-oncology in Santa Maria
- James BerensonWest Hollywood$1M
- Ari BaronSan Francisco$705K
- Jeffrey WolfSan Francisco$407K
- Haresh JhangianiFountain Valley$77K
- Mark ScholzMarina del Rey$62K
- Derrick SuFountain Valley$53K
- Peyman Salimi-TariFountain Valley$49K
- Janet PanFountain Valley$46K
- Bertrand TuanSan Francisco$45K
- Brian ChoiRiverside$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.